Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Geratherm Medical AG's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 33.81.
Geratherm Medical AG's Days Inventory for the
six
months ended in Dec. 2025 was 388.75.
Geratherm Medical AG's Days Payable for the
six
months ended in Dec. 2025 was 55.27.
Therefore, Geratherm Medical AG's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 367.29.
Geratherm Medical AG (LTS:0EL9) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Geratherm Medical AG Cash Conversion Cycle Related Terms
Geratherm Medical AG Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Geratherm Medical AG's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0EL9 vs ABT, SYK, MDT: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Geratherm Medical AG's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Geratherm Medical AG Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Geratherm Medical AG's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Geratherm Medical AG's Cash Conversion Cycle falls into.
Geratherm Medical AG Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Geratherm Medical AG's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Geratherm Medical AG (LTS:0EL9) has a Cash Conversion Cycle of 367.29 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Geratherm Medical AG and its competitors.
Is Geratherm Medical AG's Cash Conversion Cycle too high?
Geratherm Medical AG's current Cash Conversion Cycle is 367.29. The Medical Devices & Instruments industry median Cash Conversion Cycle is 158.92. Geratherm Medical AG's value of 367.29 is 131.1% above this industry median. Overall, Geratherm Medical AG has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Geratherm Medical AG's Cash Conversion Cycle compare to ABT and SYK?
Geratherm Medical AG's Cash Conversion Cycle of 367.29 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 158.92. Geratherm Medical AG's value of 367.29 is 131.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 158.92, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Geratherm Medical AG's current Cash Conversion Cycle of 367.29 is 131.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Geratherm Medical AG and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 158.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Geratherm Medical AG's current Cash Conversion Cycle is 367.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geratherm Medical AG stock overvalued right now?
Geratherm Medical AG (LTS:0EL9) has a current Cash Conversion Cycle of 367.29. The stock's GF Value™ is €3.25, compared to a current price of €2.60 — trading 20% below its estimated fair value. The current Cash Conversion Cycle is 367.29 and 131.1% above the Medical Devices & Instruments industry median of 158.92. Geratherm Medical AG's overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Geratherm Medical AG (LTS:0EL9), the current Cash Conversion Cycle is 367.29 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Geratherm Medical AG (LTS:0EL9) Overvalued in 2026?
Based on GuruFocus' analysis, Geratherm Medical AG stock appears to be undervalued.
The current stock price of €2.60 is trading 20% below its estimated GF Value™ of €3.25.
Key valuation signals for LTS:0EL9:
Cash Conversion Cycle: 367.29
GF Value™: €3.25 vs. price of €2.60 (20% below fair value)
Industry Position: 131.1% above the Medical Devices & Instruments median
No single metric tells the full story. See the LTS:0EL9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Geratherm Medical AG is a Germany-based medical technology company. The firm operates through four segments: Healthcare Diagnostic, Medical Warming Systems, Cardio/Stroke and Respiratory. Healthcare Diagnostic segment which generates majority revenue provides analog and digital products for measuring body temperature, blood pressure monitors and other products for measuring temperature, as well as related accessories. Medical Warming Systems offers solutions for temperature management at all stages in the pre-clinical and clinical care of the patients, such as rescue situations and operations. Cardio/Stroke segment comprises products for preventing strokes. The Respiratory segment focuses on the development and production of products for pulmonary functional diagnostics.
26GF Score
Get the complete analysis for LTS:0EL9
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0EL9 has been successfully added to your 
